Optimization of statin use: genetic factors and therapeutic drug monitoring
https://doi.org/10.37489/2588-0527-2020-1-11-18
Abstract
The article is devoted to the description of the global experience of personalized prescription of statins. The prerequisites for including the genetic factor, the carriage of the c.521C allele of the gene SLCO1B1, into the statin prescribing algorithm are stated. Also set out the reasons that complicate the introduction of therapeutic drug monitoring of statins into clinical practice are described.
About the Authors
R. Ye. Kazakov
CCP FSBI «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Kazakov Ruslan Ye. - Candidate of Biology Sciences, head of the Department of Personalized medicine and clinical pharmacogenetics
Moscow
A. B. Prokofiev
CCP FSBI «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Russian Federation
Prokofiev Alexei B. - Doctor of Medical Sciences, Professor, Director of the Center for clinical pharmacology
Moscow
Russian Federation
Prokofiev Alexei B. - Doctor of Medical Sciences, Professor, Director of the Center for clinical pharmacology
Moscow
References
1. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267–1278. DOI: 10.1016/S0140-6736(05)67394-1.
2. ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Atherosclerosis. 2019 Nov;290:140-205. DOI: 10.1016/j.atherosclerosis.2019.08.014.
3. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am Coll Cardiol. 2016 May 24;67(20):2395–2410. DOI: 10.1016/j.jacc.2016.02.071.
4. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: A meta-analysis of randomized trials. CMAJ. 2008 Feb 26;178(5):576–584. DOI: 10.1503/cmaj.070675.
5. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in america and gaps in patient education (usage): An internet-based survey of 10,138 current and former statin users. J Clin Lipidol. May-Jun 2012;6(3):208–215. DOI: 10.1016/j.jacl.2012.03.003.
6. Bruckert E, Hayem G, Dejager S et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients — The primo study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403–414. DOI: 10.1007/s10557-005-5686-z.
7. Canestaro WJ, Brooks DG, Pers DC. Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing. J Pers Med. 2012 Oct 17;2(4):158–174. DOI: 10.3390/jpm2040158.
8. Котловский М.Ю., Покровский А.А., Котловская О.С. и др. Ген SLCO1B1 в аспекте фармакогенетики // Сибирское медицинское обозрение. – 2015. – № 1. – С. 5–15. [Kotlovsky MY, Pokrovskiy AA, Kotlovskaya OS et al. SLCO1B1 gene in the aspect of pharmacogenetics. Sibirskoe medicinskoe obozrenie. 2015;(1):5–15. (In Russ).]
9. Соколов А.В., Тищенко И.Ф., Белоусов Ю.Б. Оптимизация фармакотерапии на основе терапевтического лекарственного мониторинга // Лечебное дело. – 2004. – № 3. – С. 34–39. [Sokolov AV, Tishchenko IF, Belousov YuB. Optimizaciya farmakoterapii na osnove terapevticheskogo lekarstvennogo monitoringa. Lechebnoe delo. 2004;(3): 34–39. (In Russ).].
10. URL: https://cpicpgx.org/guidelines/guideline-for-simvastatin-andslco1b1/
11. URL: https://www.knmp.nl/patientenzorg/medicatiebewaking/farmacogenetica/pharmacogenetics-1/pharmacogenetics/
12. Bank PCD, Caudle KE, Swen JJ et al. Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther. 2018 Apr;103(4): 599–618. DOI: 10.1002/cpt.762.
13. Wilke RA, Ramsey LB, Johnson SG et al. The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clin Pharmacol Ther. 2012 Jul;92(1):112–117. DOI: 10.1038/clpt.2012.57.
14. Ramsey LB, Johnson SG, Caudle KE et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clin Pharmacol Ther. 2014 Oct;96(4):423–428. DOI: 10.1038/clpt.2014.125.
15. Link E, Parish S, Armitage J et al. SEARCH Collaborative Group, SLCO1B1 variants and statininduced myopathy — a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789–799. DOI: 10.1056/NEJMoa0801936.
16. Voora D, Shah SH, Spasojevic I et al. The SLCO1B1*5 Genetic Variant is Associated with Statin-Induced Side Effects. J Am Coll Cardiol. 2009 Oct 20;54(17):1609–1616. DOI: 10.1016/j.jacc.2009.04.053.
17. Lamoureux F, Duflotthe T, French Network of Pharmacogenetics (RNPGX). Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx). Therapie. 2017 Apr;72(2):257–267. DOI: 10.1016/j.therap.2016.09.017.
18. URL: https://amiko.oddb.org/de/fi?gtin=56139
19. URL: https://amiko.oddb.org/de/fi?gtin=62329&highlight=Polymorphismus
20. Сычев Д.А. Фармакогенетическое тестирование: клиническая интерпретация результатов (рекомендации для практикующих врачей). – М.: 2011. 88с. [Sychev DA. Farmakogeneticheskoe testirovanie: klinicheskaya interpretaciya rezul’tatov (rekomendacii dlya praktikuyushchih vrachej). Moscow: 2011. (In Russ).]
21. Becquemont L, Alfirevic A, Amstutz U et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. 2011 Jan;12(1):113–124. DOI: 10.2217/pgs.10.147.
22. Niemi M: Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010 Jan;87(1): 130–133. DOI: 10.1038/clpt.2009.197.
23. Swen JJ, Nijenhuis M, de Boer A et al. Pharmacogenetics: from bench to byte- an update of guidelines. Clin Pharmacol Ther. 2011 May; 89(5): 662–673. DOI: 10.1038/clpt.2011.34.
24. Wagmann L, Hemmer S, Caspar AT, Meyer MR. Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring. Clin Chem Lab Med. 2020 Apr 28;58(5):664–672. DOI: 10.1515/cclm-2019-0763.
25. Архипов ВВ, Городецкая ГИ, Демидова ОА и др. Анализ проблем безопасности применения статинов у пациентов с сахарным диабетом и гипотиреозом. Безопасность и риск фармакотерапии. 2019;7(4): 163–175. [Arkhipov VV, Gorodetskaya GI, Demidova OA et al. Analysis of Safety Issues of Using Statins in Patients with Diabetes and Hypothyroidism. Safety and Risk of Pharmacotherapy. 2019;7(4):163–175. (In Russ).] DOI: 10.30895/2312-7821-2019-7-4-163-175.
Review
For citations:
Kazakov R.Ye., Prokofiev A.B. Optimization of statin use: genetic factors and therapeutic drug monitoring. Pharmacogenetics and Pharmacogenomics. 2020;(1):11-18. (In Russ.) https://doi.org/10.37489/2588-0527-2020-1-11-18
Views:
1088
Email this article 
Post a Comment 